Filing Details

Accession Number:
0000899243-21-010471
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-08 20:40:58
Reporting Period:
2021-03-04
Accepted Time:
2021-03-08 20:40:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1799321 Istvan Molnar C/O Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica MA 01862
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-04 4,027 $18.40 25,130 No 4 S Direct
Common Stock Acquisiton 2021-03-04 33,820 $0.00 58,950 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Footnotes
  1. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
  2. Includes 157 shares acquired under the LNTH employee stock purchase plan on September 11, 2020.